Two cases of mycosis fungoides with large cell transformation with KMT2A rearrangements

Pub Date : 2023-11-23 DOI:10.1007/s12308-023-00567-2
Paul A. Wadsworth, Lauren Lawrence, Carlos J. Suarez, Atif Saleem, Michael S. Khodadoust, Youn H. Kim, Kerri E. Rieger, Sebastian Fernandez-Pol
{"title":"Two cases of mycosis fungoides with large cell transformation with KMT2A rearrangements","authors":"Paul A. Wadsworth, Lauren Lawrence, Carlos J. Suarez, Atif Saleem, Michael S. Khodadoust, Youn H. Kim, Kerri E. Rieger, Sebastian Fernandez-Pol","doi":"10.1007/s12308-023-00567-2","DOIUrl":null,"url":null,"abstract":"<p>Cutaneous T-cell lymphomas (CTCL) are a clinically and molecularly heterogeneous class of lymphomas of the skin-homing T cell, and their genetic profiles are not fully characterized. Previously, rearrangements of the Lysine Methyltransferase 2A (<i>KMT2A</i>) gene have been identified as driver mutations only in acute leukemias. <i>KMT2A</i> plays a role in epigenetic regulation, and cancers with such rearrangements are responsive to epigenetic therapy including hypomethylating agents. Here, we report two cases of CTCL with novel genetic profiles. <i>KMT2A</i> rearrangements were identified in two aggressive cases of mycosis fungoides with large cell transformation. A <i>KMT2A::DSCAML1</i> gene rearrangement was seen in Case 1, while a <i>KMT2A::MAPRE1</i> fusion was identified in Case 2. These cases demonstrate that <i>KMT2A</i> rearrangements can be found in primary CTCLs rather than solely acute leukemias, illustrating the importance of correlating molecular findings with clinical and histologic features in diagnosis. Additionally, this finding suggests that the subset of CTCLs driven by aberrancy of the <i>KMT2A</i> pathway may be responsive to therapy with hypomethylating agents or menin inhibitors, as seen in acute leukemias.</p>","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12308-023-00567-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Cutaneous T-cell lymphomas (CTCL) are a clinically and molecularly heterogeneous class of lymphomas of the skin-homing T cell, and their genetic profiles are not fully characterized. Previously, rearrangements of the Lysine Methyltransferase 2A (KMT2A) gene have been identified as driver mutations only in acute leukemias. KMT2A plays a role in epigenetic regulation, and cancers with such rearrangements are responsive to epigenetic therapy including hypomethylating agents. Here, we report two cases of CTCL with novel genetic profiles. KMT2A rearrangements were identified in two aggressive cases of mycosis fungoides with large cell transformation. A KMT2A::DSCAML1 gene rearrangement was seen in Case 1, while a KMT2A::MAPRE1 fusion was identified in Case 2. These cases demonstrate that KMT2A rearrangements can be found in primary CTCLs rather than solely acute leukemias, illustrating the importance of correlating molecular findings with clinical and histologic features in diagnosis. Additionally, this finding suggests that the subset of CTCLs driven by aberrancy of the KMT2A pathway may be responsive to therapy with hypomethylating agents or menin inhibitors, as seen in acute leukemias.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
蕈样真菌病伴大细胞转化伴KMT2A重排2例
皮肤T细胞淋巴瘤(CTCL)是临床上和分子异质性的一类皮肤归巢T细胞淋巴瘤,其遗传谱尚未完全表征。以前,赖氨酸甲基转移酶2A (KMT2A)基因的重排仅在急性白血病中被确定为驱动突变。KMT2A在表观遗传调控中发挥作用,具有这种重排的癌症对包括低甲基化药物在内的表观遗传治疗有反应。在这里,我们报告两例CTCL与新的遗传谱。KMT2A重排在两个侵袭性蕈样真菌病伴大细胞转化的病例中被发现。在病例1中发现了KMT2A::DSCAML1基因重排,而在病例2中发现了KMT2A::MAPRE1融合。这些病例表明,KMT2A重排可以在原发性ctcl中发现,而不仅仅是急性白血病,这说明了将分子发现与临床和组织学特征相关联在诊断中的重要性。此外,这一发现表明,由KMT2A途径异常驱动的ctcl亚群可能对低甲基化药物或menin抑制剂治疗有反应,如在急性白血病中所见。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1